ESMO 2022

Evolution of Prostate Cancer Research: From Prognostic Models to Biomarkers and Beyond - Michael Morris

The Use of Biomarkers in the Adjuvant Setting to Understand the Effect of Nivolumab in the Checkmate 274 Study - Andrea Necchi

The CLEAR Study: Lenvatinib + Pembro vs Sunitinib in Advanced RCC - Camillo Porta

PIVOT-09 Trial: An In-Depth Analysis of Revisiting IL-2 Therapies in Advanced RCC - Nizar Tannir

Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris

Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru Sonpavde

Predicting Efficacy of Both Nivolumab and of Nivolumab + Ipilimumab in Frontline mccRCC Patients, An Ancillary Analyses from the BIONIKK Randomized Trial - Maxime Meylan

Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay

MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer, The BladderPath Trial - Nicholas James

rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC - Fred Saad

8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam

Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi

Personalizing Prostate Cancer Care with AI - Felix Feng

Exploring the SPLASH Trial: PSMA I&T Lutetium-177 in Pre-Chemo Metastatic CRPC - Oliver Sartor

The PROSPER Trial: A Comprehensive Analysis of Neoadjuvant Nivolumab in Renal Cancer - Naomi Haas

Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard

The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore

Belzutifan Plus Cabozantinib Shows Manageable Safety with Promising Antitumor Activity In Treatment-Naïve Advanced Clear Cell RCC, The LITESPARK-003 Study - Toni K. Choueiri

(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan

Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal

Optimizing Treatment for High-Risk M0CRPC - Laura-Maria Krabbe

When and How Much: A Deep Dive into the RADICALS Trial's Questions on Radiotherapy and Hormone Therapy - Nicholas James

ODM-208: A New Hope for Treatment-Resistant Prostate Cancer - Karim Fizazi

EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonathan E. Rosenberg

The Phase III PROpel Trial in mCRPC, A Biomarker Analysis and the Detection of Mutations in HRR Genes - Noel Clarke

A Urologist's Perspective on the PROpel Trial, Olaparib and Abiraterone versus Abiraterone Alone, in the First-Line Metastatic Castration-Resistant Prostate Cancer Setting - Neal Shore

Triplet Therapy With Cabozantinib, Nivolumab, and Ipilimumab as First-line Treatment in Patients With Advanced Renal Cell Carcinoma, COSMIC 313 - Toni K. Choueiri

An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt Attard

Final Results of TITAN-RCC Trial - Is a Tailored Approach of Nivolumab and Nivolumab/Ipilimumab as Immunotherapeutic Boost Recommended - Marc-Oliver Grimm

Pembrolizumab in Combination with Lenvatinib as First-Line Treatment for Non Clear Cell Renal Cell Carcinoma (nccRCC), KEYNOTE-B61 - Laurence Albiges

Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH - Neil Fleshner